Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA.

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Shanghai Qingyu Pharmaceutical Technology Co., Ltd., established on 2016-12-22, Business scope includes general items:Medical Technology(remove human stem cells,Development and application of genetic diagnosis and treatment technology)technology development in the field,technical consulting,Technical Services,technology transfer,medicine,food,Chemical raw materials(Removal of hazardous chemicals,Monitor Chemicals,civilian explosives,precursor chemicals)research and development.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Fulcrum Therapeutics is a biotechnology company that develops new medicines to treat patients with rare genetic diseases. The company develops a proprietary product engine that is employed to identify and validate cellular drug targets that can modulate gene expression. Its product candidate, losmapimod, is a small molecule that was developed for the treatment of FSHD, a muscle-wasting disorder that leads to physical impairment and disability. It is focused on improving the lives of patients with genetically defined diseases in areas of high unmet medical need, with an initial focus on rare diseases. Founded in 2016, the company is based in Cambridge, Massachusetts, United States.

Korea Research Institute of Bioscience and Biotechnology (KRIBB) is a government research institute in Daejeon, South Korea. It is dedicated to biotechnology research across a broad span of expertise, from basic studies for the fundamental understanding of life phenomena to applied studies such as drug discovery, novel biomaterials, integrated biotechnology and bioinformation.

Suzhou Suling Biomedical Co., Ltd., established on 2014-09-15, Business scope includes biomedical research and development;medicine,Technology development of pharmaceutical intermediates,Technical consulting and technology transfer;Self-operated and agent import and export business of various commodities and technologies;sales of chemical products.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Sequenom (NASDAQ: SQNM) is an American company based in San Diego, California. It develops enabling molecular technologies, and highly sensitive laboratory genetic tests for NIPT. Sequenom's wholly owned subsidiarity, Sequenom Center for Molecular Medicine (SCMM), offers multiple clinical molecular genetics tests to patients, including MaterniT21, plus a noninvasive prenatal test for trisomy 21, trisomy 18, and trisomy 13, and the SensiGene RHD Fetal RHD genotyping test.

Nanjing Ufluoropharmaceutical Technology Co., Ltd., established on 2018-06-20, Business scope includes medical technology,Daily chemical products,Food Technology Research and Development,technical consulting,Technical Services,technology transfer;Medical information consultation(Do not engage in medical activities);Self-operated and agent import and export business of various commodities and technologies;Sales of pharmaceutical intermediates.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

The Texas A&M University System creates a seamless pathway for students to earn an associate and bachelor’s degree in related fields

HitGen, Inc. engages in the provision deoxyribonucleic acid encoded compound library (DEL) for research and development of seed and lead compounds. It offers DEL screening and library customization, chemical synthesis, and new drug research and development project transfer services. The company was founded by Jin Li on February 22, 2012 and is headquartered in Chengdu, China.

Massachusetts General Hospital was established to provide care to Boston's sick, regardless of socioeconomic status—an innovative idea in 1811. In the words of their founder, John Warren, MD, “When in distress, every man becomes their neighbor.” They subsequently became the first teaching hospital for Harvard University’s new medical school and have been redefining excellence in healthcare ever since. They have remained at the forefront of medicine by fostering a culture of collaboration, pushing the boundaries of medical research, educating the brightest medical minds and maintaining an unwavering commitment to the diverse community they were created to serve. They believe that because of diversity they excel, through inclusion they respect their community, and with a keen focus on equity they serve, heal, educate and innovate at the highest levels. Their first priority is the well-being of their patients—near and far. As a team they are able to maintain a singular focus on providing the highest quality, most compassionate care to each and every patient.

Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA.

BC Cancer Agency provides healthcare services. The firm serves for hereditary cancer, indigenous cancer care, interpreters, and psychiatry. Its services include assessment and follow-up library, nutrition services, pain and symptom management, patient and family counselling, PET functional imaging, primary care, screening programs, and speech-language pathology. The company was founded on November 5, 1938 and is headquartered in Vancouver, Canada.

Institut Jean Paoli & Irene Calmettes is a non-profit organization engaging in fighting cancer. The company is headquartered in Marseille, France.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Tianjin Medical University General Hospital (Chinese: 天津医科大学总医院) is a general hospital in the central Heping District of the Chinese metropolis of Tianjin, associated with Tianjin Medical University.

Qingyu Pharmaceutical R&D (Shanghai) Co., Ltd., established on 2020-12-16, Business scope includes general items:Medical Technology(human stem cells,Except for the development and application of genetic diagnosis and treatment technology)technology development in the field,technical consulting,Technical Services,Technical Support,technology transfer(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).licensed items:Drug Wholesale(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments).